PDCD1 and cancer: Multiple clinical trials are currently investigating the use of TIM-3, TIGIT and LAG-3 as targets for monotherapy or in combination with anti-PD-1 and have shown promise for cancer therapy90,217,218,226 (Fig. 3 and Table 1).